Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SYRE 
Spyre Therapeutics Inc. (SYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/17/2025: SYRE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $53.58
1 Year Target Price $53.58
| 10 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -22.39% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.56B USD | Price to earnings Ratio - | 1Y Target Price 53.58 |
Price to earnings Ratio - | 1Y Target Price 53.58 | ||
Volume (30-day avg) 11 | Beta 3.15 | 52 Weeks Range 10.91 - 35.31 | Updated Date 12/17/2025 |
52 Weeks Range 10.91 - 35.31 | Updated Date 12/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.2% | Return on Equity (TTM) -38.08% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2403862526 | Price to Sales(TTM) 650.22 |
Enterprise Value 2403862526 | Price to Sales(TTM) 650.22 | ||
Enterprise Value to Revenue 1964.91 | Enterprise Value to EBITDA -7.96 | Shares Outstanding 77592130 | Shares Floating 67572658 |
Shares Outstanding 77592130 | Shares Floating 67572658 | ||
Percent Insiders 6.7 | Percent Institutions 84.3 |
About Spyre Therapeutics Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2016-04-07 | CEO & Director Dr. Cameron Turtle DPHIL, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 95 | Website https://www.spyre.com |
Full time employees 95 | Website https://www.spyre.com | ||
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.